Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma

Wednesday, January 13, 2016 7:04 pm EST

Dateline:

SHANGHAI

Public Company Information:

NYSE:
PFE
US7170811035
"Forward-Looking Information and Factors That May Affect Future Results"

SHANGHAI--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has acquired Sirio Pharma Co. Ltd.’s wholly-owned subsidiary, Treerly Health Co., Ltd., and its family of Treerly products.

Treerly is one of the top healthcare brands in China’s retail channel and consists of an extensive portfolio of products uniquely designed to meet women’s nutritional healthcare needs throughout their lives. The Treerly portfolio complements Pfizer Consumer Healthcare’s product portfolio in China and will strengthen its position as a leading provider of over-the-counter (OTC) dietary supplements. Pfizer Consumer Healthcare’s Caltrate® calcium supplements and Centrum® multivitamin supplements are among the top three brands in the OTC vitamin and minerals supplement category in China.

Sirio Pharma is a private, closely-held contract manufacturing company in China that produces dietary supplements and drugs. Sirio is currently a qualified third-party supplier to Pfizer Consumer Healthcare. Under the terms of the agreement, Sirio will continue to supply the high-quality Treerly family of products to Pfizer Consumer Healthcare.

“The acquisition of the Treerly brand and its family of products will enhance the portfolio of dietary supplements we offer to our retail customers in China and will enable us to help more consumers improve their health and well-being,” said Keith Choy, regional president, Asia Pacific, Pfizer Consumer Healthcare. “The addition of the Treerly products will also make it possible to leverage our existing sales and marketing capabilities and be more efficient in launching future innovations for consumers in China,” he said.

Pfizer in China

Pfizer has been doing business in China since the 1980s and employs approximately 10,000 colleagues there, with approximately 1,400 working in Pfizer Consumer Healthcare. Currently,Pfizer operates in 300 cities throughout China, has three other production facilities in the country in addition to its operations in Suzhou, and operates two world-class research and development centers in China. To learn more, please visit www.pfizer.com.cn.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of January 13, 2016. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information related to Pfizer, Treerly Health Co. (Treerly) and the acquisition of Treerly by Pfizer that involves substantial risks and uncertainties. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the acquisition[, including the possibility that expected synergies will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange or interest rates; changes in tax laws, regulations, rates and policies; the uncertainties inherent in research and development]; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Contact:

Pfizer Inc.
Sally Beatty, 212-733-6566
sally.beatty@pfizer.com
or
Ouyang Jie – China
86-10 8516 7345
jie.ouyang@pfizer.com